Kenji Tanimura

ORCID: 0000-0003-1435-120X · 6 papers in corpus
observational 2025
Frontiers in immunology ·doi:10.3389/fimmu.2025.1626862

OBJECTIVE: This study aimed to assess whether anti-β2-glycoprotein I (β2GPI)/human leukocyte antigen (HLA)-DR autoantibodies are associated with pregnancy outcomes in women with infertility receiving assisted reproductive technology (ART) i…

observational 2024
Frontiers in immunology ·doi:10.3389/fimmu.2024.1445852

INTRODUCTION: Anti-β2-glycoprotein I (β2GPI)/human leukocyte antigen (HLA)-DR antibodies may be a risk factor for recurrent pregnancy loss (RPL). The therapeutic modality for women with RPL and anti-β2GPI/HLA-DR antibody positivity has not …

observational 2023
International journal of molecular sciences ·doi:10.3390/ijms241310958

Anti-β2-glycoprotein I/HLA-DR (anti-β2GPI/HLA-DR) antibody has been reported to be associated with antiphospholipid syndrome and recurrent pregnancy loss (RPL). We conducted a prospective multicenter cross-sectional study aimed at evaluatin…

observational 2023
Journal of Reproductive Immunology ·doi:10.1016/j.jri.2023.103955

To evaluate whether anti-β2-Glycoprotein I/HLA-DR (anti-β2GPI/HLA-DR) antibody is associated with pathophysiology of infertility, 224 women with infertility were enrolled from July 2020 to December 2021 in this prospective study. The serum …

2022
·doi:10.1016/j.jri.2022.103732
2018
·doi:10.1016/j.jri.2018.09.044